CRISPR/Cas9 technology generated an arginine to glutamine substitution at amino acid 156 (p.R156Q). This corresponds to one of the human variants, p.R158Q, identified in Gitelman syndrome. (J:336073)
查看原文 参与反馈
CRISPR/Cas9 technology generated an arginine to glutamine substitution at amino acid 156 (p.R156Q). This corresponds to one of the human variants, p.R158Q, identified in Gitelman syndrome. (J:336073)